TY - JOUR
T1 - Primary CNS lymphoma of T-cell origin
T2 - A descriptive analysis from the international primary CNS Lymphoma Collaborative Group
AU - Shenkier, Tamara N.
AU - Blay, Jean Yves
AU - O'Neill, Brian Patrick
AU - Poortmans, Philip
AU - Thiel, Eckhard
AU - Jahnke, Kristoph
AU - Abrey, Lauren E.
AU - Neuwelt, Edward
AU - Tsang, Richard
AU - Batchelor, Tracy
AU - Harris, Nancy
AU - Ferreri, Andrés J.M.
AU - Ponzoni, Maurilio
AU - O'Brien, Peter
AU - Rubenstein, James
AU - Connors, Joseph M.
PY - 2005
Y1 - 2005
N2 - Purpose: To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). Patients and Methods: A retrospective series of patients with TPCNSL was compiled from twelve cancer centers in seven countries. Results: We identified 45 patients with a median age of 60 years (range, 3 to 84 years). Twenty (44%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Twenty-six (58%) had involvement of a cerebral hemisphere and sixteen (36%) had lesions of deeper sites in the brain. Serum lactate dehydrogenase was elevated in 7 (32%) of 22 patients, and CSF protein was elevated in 19 of 24 patients (79%) with available data. The median disease-specific survival (DSS) was 25 months (95% CI, 11 to 38 months). The 2- and 5-year DSS were 51% (95% CI, 35% to 66%) and 17% (95% CI, 6% to 34%), respectively. Univariate and multivariate analyses were conducted for age (≤ 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no). Only PS and MTX use were significantly associated with better outcome with hazard ratios of 0.2 (95% CI, 0.1 to 0.4) and 0.4 (95% CI, 0.2 to 0.8), respectively. Conclusion: This is the largest series ever assembled of TPCNSL. The presentation and outcome appear similar to that of B cell PCNSL. PS 0 or 1 and administration of MTX are associated with better survival.
AB - Purpose: To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). Patients and Methods: A retrospective series of patients with TPCNSL was compiled from twelve cancer centers in seven countries. Results: We identified 45 patients with a median age of 60 years (range, 3 to 84 years). Twenty (44%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Twenty-six (58%) had involvement of a cerebral hemisphere and sixteen (36%) had lesions of deeper sites in the brain. Serum lactate dehydrogenase was elevated in 7 (32%) of 22 patients, and CSF protein was elevated in 19 of 24 patients (79%) with available data. The median disease-specific survival (DSS) was 25 months (95% CI, 11 to 38 months). The 2- and 5-year DSS were 51% (95% CI, 35% to 66%) and 17% (95% CI, 6% to 34%), respectively. Univariate and multivariate analyses were conducted for age (≤ 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no). Only PS and MTX use were significantly associated with better outcome with hazard ratios of 0.2 (95% CI, 0.1 to 0.4) and 0.4 (95% CI, 0.2 to 0.8), respectively. Conclusion: This is the largest series ever assembled of TPCNSL. The presentation and outcome appear similar to that of B cell PCNSL. PS 0 or 1 and administration of MTX are associated with better survival.
UR - http://www.scopus.com/inward/record.url?scp=20244383617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20244383617&partnerID=8YFLogxK
U2 - 10.1200/JCO.2005.07.109
DO - 10.1200/JCO.2005.07.109
M3 - Article
C2 - 15800313
AN - SCOPUS:20244383617
SN - 0732-183X
VL - 23
SP - 2233
EP - 2239
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 10
ER -